Abstract | AIMS: METHODS AND RESULTS: We pooled individual patient-level data from three randomised clinical trials (ISAR-TEST-3, ISAR-TEST-4 and LEADERS) comparing outcomes from BP-DES with DP-SES at four years. The primary endpoint ( MACE) comprised cardiac death, MI, or target lesion revascularisation (TLR). Secondary endpoints were TLR, cardiac death or MI, and definite or probable stent thrombosis. Of 497 patients with STEMI, 291 received BP-DES and 206 DP-SES. At four years, MACE was significantly reduced following treatment with BP-DES (hazard ratio [HR] 0.59, 95% CI: 0.39-0.90; p=0.01) driven by reduced TLR (HR 0.54, 95% CI: 0.30-0.98; p=0.04). Trends towards reduction were seen for cardiac death or MI (HR 0.63, 95% CI: 0.37-1.05; p=0.07) and definite or probable stent thrombosis (3.6% vs. 7.1%; HR 0.49, 95% CI: 0.22-1.11; p=0.09). CONCLUSIONS:
|
Authors | Antoinette de Waha, Lamin A King, Giulio G Stefanini, Robert A Byrne, Patrick W Serruys, Bernhard Meier, Peter Jüni, Adnan Kastrati, Stephan Windecker |
Journal | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
(EuroIntervention)
Vol. 10
Issue 12
Pg. 1425-31
(Apr 2015)
ISSN: 1969-6213 [Electronic] France |
PMID | 24602961
(Publication Type: Clinical Study, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibiotics, Antineoplastic
- Polymers
- Sirolimus
|
Topics |
- Absorbable Implants
- Aged
- Antibiotics, Antineoplastic
(therapeutic use)
- Coronary Artery Disease
(therapy)
- Coronary Stenosis
(therapy)
- Drug-Eluting Stents
- Female
- Humans
- Male
- Middle Aged
- Myocardial Infarction
(therapy)
- Percutaneous Coronary Intervention
(methods)
- Polymers
- Prosthesis Design
- Randomized Controlled Trials as Topic
- Sirolimus
(therapeutic use)
- Thrombosis
(epidemiology, therapy)
- Treatment Outcome
|